First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
会议论文
Shen Lin,Bai Yuxian,Lin Xiaoyan, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. [J].JOURNAL OF CLINICAL ONCOLOGY,2025,43(4_SUPPL):392-392.
APA：
Shen Lin,Bai Yuxian,Lin Xiaoyan,Li Wei,&Liu Tianshu.(2025).First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. .JOURNAL OF CLINICAL ONCOLOGY,43(4_SUPPL):392-392.
MLA：
Shen Lin, et al. "First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649." .JOURNAL OF CLINICAL ONCOLOGY 43,4_SUPPL(2025):392-392.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
作者：
Shen, Lin ;Bai, Yuxian ;Lin, Xiaoyan ;Li, Wei ;Wang, Jufeng ;Zhang, Xiaochun ;Pan, Hongming ;Bai, Chunmei ;Bai, Li ;Cheng, Ying ;Zhang, Jingdong ;Zhong, Haijun ;Ba, Yi ;Hu, Wenwei ;Xu, Rui-Hua ;Guo, Weijian ;Qin, Shukui ;Hu, Nan ;McCraith, Stephen ;Liu, Tianshu
来源出版物：
JOURNAL OF CLINICAL ONCOLOGY
2025 年43 卷4_SUPPL 期(392 - 392)
增刊：
4_SUPPL
出版日期：
2025 FEB
ISSN/EISSN：
0732-183X /1527-7755
地址：
Beijing Canc Hosp, Beijing, Peoples R China. Harbin Med Univ, Affiliated Tumor Hosp, Harbin, Heilongjiang, Peoples R China. Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China. First Hosp Jilin Univ, Changchun, Jilin, Peoples R China. Affiliated Canc Hosp Zhengzhou Univ, Henan Canc Hosp, Zhengzhou, Peoples R China. Henan Canc Hosp, Zhengzhou, Peoples R China. Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China. Sir Run Run Shaw Hosp, Hangzhou, Peoples R China. Peking Union Med Coll Hosp, Beijing, Peoples R China. 301 Hosp, Chinese PLA Gen Hosp, Beijing, Peoples R China. Jilin Canc Hosp, Changchun, Peoples R China. Liaoning Canc Hosp & Inst, Shenyang, Peoples R China. Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China. Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China. First Peoples Hosp Changzhou, Changzhou, Peoples R China. Sun Yat sen Univ, Med Oncol, Guangzhou, Peoples R China. Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China. China Pharmaceut Univ, Nanjing Tianyinshan Hosp, Nanjing, Peoples R China. Bristol Myers Squibb, Princeton, NJ USA. Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.
(8.0+极速模式)